Abstract: Community acquired pneumonia (CAP) is a worldwide disease with the high incidence rate and high mortality, and it is one of the main causes leading to death and hospitalization among all age groups, which greatly consumes health, social and economic resources. Timely and appropriate antibiotic treatment is very important to improve the prognosis of CAP patients. The clinical benefit of β-lactams combined with macrolides still remains controversial in the treatment of CAP. This study reviewed the progress of β-lactams combined with macrolides in the treatment of adult patients with CAP.